Fortress Biotech, Inc. revenue by segment FBIO

Annual Quarterly

Fortress Biotech, Inc. splits its revenue into 13 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Qbrexza at $25.0 million, 41% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	67	61	55	60	71	63	45	35	23	17	16
Qbrexza	23 -9.2% share 34.5%	25 share 40.8%	—	—	—	17 share 27.0%	—	—	—	—	—
Emrosi	24 share 36.2%	15 share 24.1%	—	—	—	—	—	—	—	—	—
Accutane	13 -16.2% share 18.7%	13 -33.6% share 21.0%	19 share 35.2%	—	18 +82.8% share 25.9%	10 share 15.9%	—	—	—	—	—
Foam Franchise Products	5 share 7.8%	6 share 9.6%	—	—	—	—	—	—	—	—	—
Amzeeq	—	—	5 -19.2% share 9.1%	6 share 10.4%	—	—	—	—	—	—	—
Exelderm	—	—	—	—	3 -35.4% share 4.9%	5 +20.4% share 8.5%	4 share 10.0%	—	—	—	—
Targadox	—	—	—	3 -59.8% share 5.4%	8 share 11.2%	—	31 share 69.0%	—	—	—	—
Other Legacy Product Revenue	2 -49.4% share 2.7%	3 -30.9% share 4.5%	4 share 7.2%	—	—	—	—	—	—	—	—
Zilxi	—	—	2 -16.3% share 3.0%	2 -13.7% share 3.3%	2 share 3.2%	—	—	—	—	—	—
Collaborationrevenue	—	—	2 share 2.7%	—	—	—	—	—	—	—	—
Ximino	—	—	—	0 -94.2% share 0.5%	5 -39.9% share 7.0%	8 -13.4% share 13.1%	10 share 21.4%	—	—	—	—
Other Branded Revenue	—	—	—	—	—	0 +125.0% share 0.1%	-0 share -0.3%	—	—	—	—
Luxamend	—	—	—	0 share 0.1%	—	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: FBIO (Nasdaq), FBIOP (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Bay Harbor Islands, FL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1429260
Former names: Fortress Biotech, Inc. (until Oct 29, 2026); CORONADO BIOSCIENCES INC (until Apr 27, 2015)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.